DOI QR코드

DOI QR Code

Insulin activates EGFR by stimulating its interaction with IGF-1R in low-EGFR-expressing TNBC cells

  • Shin, Miyoung ;
  • Yang, Eun Gyeong ;
  • Song, Hyun Kyu ;
  • Jeon, Hyesung
  • Received : 2014.07.31
  • Accepted : 2014.10.21
  • Published : 2015.06.30

Abstract

The expression of epidermal growth factor receptor (EGFR) is an important diagnostic marker for triple-negative breast cancer (TNBC) cells, which lack three hormonal receptors: estrogen and progesterone receptors as well as epidermal growth factor receptor 2. EGFR transactivation can cause drug resistance in many cancers including TNBC, but the mechanism underlying this phenomenon is poorly defined. Here, we demonstrate that insulin treatment induces EGFR activation by stimulating the interaction of EGFR with insulin-like growth factor receptor 1 (IGF-1R) in the MDA-MB-436 TNBC cell line. These cells express low levels of EGFR, while exhibiting high levels of IGF-1R expression and phosphorylation. Low-EGFRexpressing MDA-MB-436 cells show high sensitivity to insulinstimulated cell growth. Therefore, unexpectedly, insulin stimulation induced EGFR transactivation by regulating its interaction with IGF-1R in low-EGFR-expressing TNBC cells. [BMB Reports 2015; 48(6): 342-347]

Keywords

EGFR activation;IGF-1R interaction;Insulin;MDA-MB-436;Triple-negative breast cancer cells

References

  1. McClelland RA, Barrow D, Madden TA et al (2001) Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology 142, 2776-2788 https://doi.org/10.1210/endo.142.7.8259
  2. Jones HE, Goddard L, Gee JM et al (2004) Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 11, 793-814 https://doi.org/10.1677/erc.1.00799
  3. Knowlden JM, Hutcheson IR, Jones HE et al (2003) Elevated levels of epidermal growth factor receptor/ c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144, 1032-1044 https://doi.org/10.1210/en.2002-220620
  4. Jin Q and Esteva FJ (2008) Cross-talk between the ErbB/ HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer. J Mammary Gland Biol Neoplasia 13, 485-498 https://doi.org/10.1007/s10911-008-9107-3
  5. Chakravarti A, Loeffler JS and Dyson NJ (2002) Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 62, 200-207
  6. Liu B, Fang M, Lu Y, Mendelsohn J and Fan Z (2001) Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody. Oncogene 20, 1913-1922 https://doi.org/10.1038/sj.onc.1204277
  7. Morgillo F, Woo JK, Kim ES, Hong WK and Lee HY (2006) Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res 66, 10100-10111 https://doi.org/10.1158/0008-5472.CAN-06-1684
  8. Sachdev D and Yee D (2006) Inhibitors of insulin-like growth factor signaling: a therapeutic approach for breast cancer. J Mammary Gland Biol Neoplasia 11, 27-39 https://doi.org/10.1007/s10911-006-9010-8
  9. Carboni JM, Wittman M, Yang Z et al (2009) BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. Mol Cancer Ther 8, 3341-3349 https://doi.org/10.1158/1535-7163.MCT-09-0499
  10. Haluska P, Carboni JM, TenEyck C et al (2008) HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. Mol Cancer Ther 7, 2589-2598 https://doi.org/10.1158/1535-7163.MCT-08-0493
  11. Fan QW, Cheng CK, Nicolaides TP et al (2007) A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res 67, 7960-7965 https://doi.org/10.1158/0008-5472.CAN-07-2154
  12. Jones RB, Gordus A, Krall JA and MacBeath G (2006) A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature 439, 168-174 https://doi.org/10.1038/nature04177
  13. Riedemann J, Takiguchi M, Sohail M and Macaulay VM (2007) The EGF receptor interacts with the type 1 IGF receptor and regulates its stability. Biochem Biophys Res Commun 355, 707-714 https://doi.org/10.1016/j.bbrc.2007.02.012
  14. Ryu JH, Shin M, Kim SA et al (2013) In vivo fluorescence imaging for cancer diagnosis using receptor-targeted epidermal growth factor-based nanoprobe. Biomaterials 34, 9149-9159 https://doi.org/10.1016/j.biomaterials.2013.08.026
  15. Yarden Y and Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2, 127-137 https://doi.org/10.1038/35052073
  16. Lehmann BD, Bauer JA, Chen X et al (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121, 2750-2767 https://doi.org/10.1172/JCI45014
  17. Yamasaki F, Zhang D, Bartholomeusz C et al (2007) Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity. Mol Cancer Ther 6, 2168-2177 https://doi.org/10.1158/1535-7163.MCT-06-0514
  18. Gallagher EJ and LeRoith D (2010) The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol Metab 21, 610-618 https://doi.org/10.1016/j.tem.2010.06.007
  19. Rakha EA and Chan S (2011) Metastatic triple-negative breast cancer. Clin Oncol 23, 587-600 https://doi.org/10.1016/j.clon.2011.03.013
  20. Nielsen TO, Hsu FD, Jensen K et al (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10, 5367-5374 https://doi.org/10.1158/1078-0432.CCR-04-0220
  21. DiGiovanni J, Kiguchi K, Frijhoff A et al (2000) Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. Proc Natl Acad Sci U S A 97, 3455-3460 https://doi.org/10.1073/pnas.97.7.3455
  22. Carboni JM, Lee AV, Hadsell DL et al (2005) Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. Cancer Res 65, 3781-3787 https://doi.org/10.1158/0008-5472.CAN-04-4602
  23. Lee CT, Park KH, Adachi Y et al (2003) Recombinant adenoviruses expressing dominant negative insulin-like growth factor-I receptor demonstrate antitumor effects on lung cancer. Cancer Gene Ther 10, 57-63 https://doi.org/10.1038/sj.cgt.7700524
  24. Pollak M (2008) Targeting insulin and insulin-like growth factor signalling in oncology. Curr Opin Pharmacol 8, 384-392 https://doi.org/10.1016/j.coph.2008.07.004
  25. Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8, 915-928 https://doi.org/10.1038/nrc2536
  26. Fierz Y, Novosyadlyy R, Vijayakumar A, Yakar S and LeRoith D (2010) Insulin-sensitizing therapy attenuates type 2 diabetes-mediated mammary tumor progression. Diabetes 59, 686-693 https://doi.org/10.2337/db09-1291

Cited by

  1. Akt1-Inhibitor of DNA binding2 is essential for growth cone formation and axon growth and promotes central nervous system axon regeneration vol.5, 2016, https://doi.org/10.7554/eLife.20799
  2. Akt regulates neurite growth by phosphorylation-dependent inhibition of radixin proteasomal degradation vol.8, pp.1, 2018, https://doi.org/10.1038/s41598-018-20755-w